Fortis Healthcare is India’s second-largest hospital chain by market value, but it is really a turnaround story built on a single decision: in 2018, Malaysian healthcare giant IHH Healthcare took control, injected fresh capital, and installed a new management team that replaced a sprawling, loss-making structure with a focused, cluster-based model. The company now operates 36 hospitals and a national diagnostics network under the Agilus brand, and its recurring approach is to concentrate beds, doctors, and equipment in a handful of urban clusters-Delhi NCR, Punjab, Karnataka, Maharashtra, and West Bengal-so that each new facility feeds off the reputation and resources of the ones already there. That philosophy of density over dispersal explains almost every move the company makes, from acquiring a hospital next door to its existing Punjab stronghold to signing a management contract for a cluster of IHH-owned hospitals in India. # Business segments Two businesses that feed each other-a hospital network that treats the most complex cases and a diagnostics chain that runs the tests those cases require, both operating under a single parent and sharing the same brand promise. ## 1. Hospitals: where the group’s clinical reputation is built **A network of 36 multi-specialty hospitals that earn revenue from every occupied bed, every surgery, and every outpatient consultation, with a deliberate tilt toward the six specialties that bring in nearly two-thirds of the business.** - **Paid by the procedure and the bed-night** - the hospital business generates revenue from inpatient stays, outpatient visits, surgeries, and diagnostic procedures, with key levers being how many beds are filled (occupancy was 68% in FY26), the average revenue per occupied bed (INR 2.51 crores per year), and the mix of paying patients, which spans cash-paying domestic patients (34%), insured patients via third-party administrators (36.3%), international patients (7.8%), and government scheme beneficiaries. - **Six specialties carry the load** - Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopedics, and Renal Sciences together contributed 62% of hospital revenue in FY26, which means the network’s investment in robots, cath labs, and transplant programmes is concentrated where the clinical and financial returns are highest. - **Brownfield beats greenfield** - the company prefers adding beds to existing hospitals over building new ones from scratch, because a brownfield expansion absorbs patients immediately and improves margins right away, whereas a greenfield hospital takes 18-24 months just to break even on cash; in FY26, roughly 250 beds were added this way, primarily in Manesar, Noida, and Faridabad. - **Inorganic moves fill the map** - in FY26, the company bought a 228-bed hospital in Jalandhar (strengthening its Punjab cluster from roughly 800 beds to over 1,000) and a 125-bed hospital in Bengaluru’s Yeshwanthpur, while also signing a 15-year lease for a 200-bed facility in Greater Noida that it had previously managed under contract. ## 2. Diagnostics: the testing engine that runs on doctor prescriptions **A pan-India chain of over 400 labs and 4,400 customer touchpoints that processed nearly 41 million tests in FY26, earning a fee on every blood draw, biopsy, and genetic panel ordered by a physician.** - **Hub-and-spoke keeps costs in check** - reference labs in major cities handle complex and specialised tests, while smaller stat labs and collection centres closer to patients handle routine work, which allows the business to offer advanced genomic sequencing on an Illumina NovaSeq X platform at one end and a basic blood panel at the other. - **Specialised tests lift the average bill** - the product mix is 53% routine, 34% specialised, and 13% wellness, but the company keeps adding high-value tests (50 new ones in FY26 alone, including hereditary cancer panels and whole exome sequencing) because a specialised test commands a higher price and is harder for a local lab to replicate. - **Wellness is the fastest-growing slice** - preventive health and wellness revenue grew 21% in FY26 and now makes up 13% of the diagnostic mix, driven partly by a loyalty programme called Club Agilus that has enrolled 3.4 million customers and rewards repeat testing. - **International samples, processed in India** - the business has operated an international division for over two decades, with a wholly-owned lab in Dubai, a joint venture in Nepal, and franchisee labs in Afghanistan and Kazakhstan; samples are shipped in temperature-controlled conditions to Indian reference labs, and reports are delivered in real time. # Group structure and partners **The entire enterprise sits under IHH Healthcare of Malaysia, which holds a 31.17% stake and exercises control through its board majority, while a multi-year effort to simplify the subsidiary maze is now largely complete.** - **IHH is the controlling shareholder** - Northern TK Venture, an indirect IHH subsidiary, acquired its stake through a INR 4,000 crore preferential allotment in November 2018, and a long-pending open offer was finally completed in November 2025, though IHH’s shareholding remained unchanged at 31.17% post-offer. - **Agilus is now almost wholly owned** - Fortis held 89.2% of Agilus Diagnostics as of January 2025, after buying out three private-equity investors-IFC, NYLIM Jacob Ballas, and Resurgence PE-who had exercised a put option under a 2012 shareholders’ agreement. - **Two merger schemes untangled the hospital subsidiaries** - a composite scheme effective September 2025 rationalised International Hospital Limited, Fortis Hospitals Limited, and Fortis Hospotel Limited, and a second scheme effective March 2026 merged four more wholly-owned subsidiaries into Fortis Hospitals Limited, all aimed at cutting administrative overhead and simplifying financial reporting. - **The Fortis brand is now owned, not rented** - the company acquired the ‘Fortis’ brand and trademarks outright for INR 200 crores via a public auction held on 21st December 2024, with the Certificate of Sale issued on 21st April 2025, ending a long period of licensing uncertainty that had once prompted the board to consider switching to IHH’s ‘Parkway’ brand.